HOME >> MEDICINE >> NEWS
Evidence Shows Drug-Psychotherapy Combo Effective For Chronic Depression

WASHINGTON, D.C. -- A new combination of drug treatment and psychotherapy is much more effective than either medication or therapy alone for treating chronic depression, according to preliminary results presented Tuesday, May 18, at the annual meeting of the American Psychiatric Association.

The combination treatment, involving the drug nefazodone and a form of psychotherapy developed specifically to treat chronic depression, also produced the highest response and remission rates for any reported study of chronic depression.

The findings come from the Serzone Chronic Depression Study, the first major study of medication alone, psychotherapy alone, and the combination of both in patients with chronic depression. Nefazodone, prescribed under the brand name Serzone, is used to treat depression and is effective for reducing relapse. The research is funded by Bristol-Myers Squibb Company, makers of Serzone.

Results from the acute phase - the first 12 weeks - of the 80-week study of 681 patients depressed for at least two years shows that a combination of nefazodone and psychotherapy produces an 85 percent response rate. The drug alone leads to a 55 percent rate of response, similar to a 52 percent response rate for psychotherapy.

Nefazodone, alone or in combination therapy, was also associated with improvement in patients much sooner than psychotherapy. The drug also provided significant early and ongoing improvement in insomnia, which is common in chronically depressed patients.

"The extremely large difference in response rates after 12 weeks is truly astonishing," said lead researcher Martin B. Keller, M.D. "This study should put to rest the widespread belief that chronic depression is resistant to drug treatments and psychotherapy." Keller is professor and chairman of the Department of Psychiatry and Human
'"/>

Contact: Scott Turner
Scott_Turner@Brown.edu
401-863-1862
Brown University
18-May-1999


Page: 1 2 3

Related medicine news :

1. Evidence indicates cancer patients unable to intentionally postpone death for significant events
2. Not guilty! Evidence exonerates 328, but many still falsely imprisoned
3. Evidence for shaken baby syndrome is uncertain
4. Evidence suggests that the brain can switch to automatic pilot during learning
5. Evidence that memories are consolidated during sleep
6. Evidence that neurons prune only twigs to rewire themselves
7. Evidence supports two types of heart failure
8. Evidence for warts treatments is weak
9. Evidence does not support psychological treatments for epilepsy
10. Evidence of PSA screening efficacy lacking
11. DDW Studies Present Evidence That Thalomid (Thalidomide) Is Active In Treating Crohns Disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology:
Cached News: